$EVGN

RECANATI LEON purchased 800,000 shares of Evogene Ltd. (EVGN) at $0.50 ($0.40M total) on 2026-08-04.

EverGen Infrastructure Corp. reported Q2 2026 RNG production of 54,675 GJ, up 3.6% from Q1 2026 and 10.9% from Q2 2025. The company also retained Red Cloud Securities as its sole market maker, paying a $5,000 monthly fee, replacing its prior arrangement. EverGen trades on TSXV: EVGN and OTCQB: EVGIF.

Evogene (Nasdaq/TASE: EVGN) and Tel Aviv University’s Blavatnik Center for Drug Discovery announced a joint initiative to accelerate AI-driven small-molecule drug discovery. The program will use Evogene’s ChemPass AI™ generative engine and BCDD experimental infrastructure in an integrated Design-Make-Test-Analyze workflow to support selected academic and entrepreneurial projects.

EverGen Infrastructure Corp. (TSXV:EVGN, OTCQB:EVGIF) said it granted deferred share units (150,000 DSUs) and restricted share units (412,919 RSUs) to certain officers and directors on June 30, 2026 under its Equity Incentive Plan. The release provides company background and includes forward-looking statements.

Evogene Ltd, an AI-focused biotech company, has garnered attention after securing new funding through a registered direct offering and private placement. This financing aims to support its AI-enabled biotechnology platforms and diverse subsidiary pipelines in human health, agriculture, and biomaterials. The company utilizes a Computational Predictive Biology (CPB) platform and a hybrid asset-light model, relying on partnerships for commercialization while focusing on discovery and early development through its subsidiaries like Biomica, Lavie Bio, AgPlenus, and Canonic.

Armistice Capital, LLC and Steven Boyd have reported a 9.99% beneficial ownership stake in Evogene Ltd. (EVGN), amounting to 1,104,906 ordinary shares, as detailed in a Schedule 13G SEC filing dated May 15, 2026, with the position as of March 31, 2026. Armistice Capital, as the investment manager for Armistice Capital Master Fund Ltd., exercises shared voting and dispositive power over these shares, indicating a passive investment strategy. The Master Fund disclaims beneficial ownership due to its investment management agreement with Armistice Capital.

Evogene (NASDAQ: EVGN) is scheduled to release its Q1 2026 financial results on May 20, 2026, and will host a live Zoom conference call the same day at 9:00 AM ET. The company has historically seen negative stock movements following earnings-related announcements due to ongoing operating losses and restructuring. Investors can register for the call and a replay will be available online afterward.

Evogene announced it will release its first quarter 2026 financial results on Wednesday, May 20, 2026. Following the release, company management will host a conference call at 9:00 AM ET to discuss the results. Evogene specializes in computational chemistry and generative AI for small molecule design in pharmaceutical and agricultural industries, using its ChemPass AI™ technology.

Evogene, a computational chemistry company, is collaborating with Queensland University of Technology (QUT) to discover and optimize new small molecules for treating chemotherapy-resistant non-small cell lung cancer (NSCLC) and other cancers. The partnership combines Evogene's ChemPass AI™ for generative molecular design with QUT's expertise in cancer cell biology, focusing on overcoming cisplatin resistance by targeting a novel cellular detoxification pathway. This initiative aims to provide new therapeutic strategies for patients with limited treatment options.

Evogene Ltd. has entered into a warrant inducement agreement with an existing institutional investor, generating approximately $3.4 million in gross proceeds. The company will use the proceeds for working capital and general corporate purposes, while the investor will receive new unregistered warrants. This transaction follows other recent positive developments for Evogene, including an expanded collaboration with Google Cloud and a licensing agreement for a microbiome-based cancer therapeutic.